Current evidence showed that inhibitors for immune checkpoint molecules such as CTLA-4, PD-1, and PD-L1 are beneficial in the management of various malignancies, such as lung cancer, malignant melanoma, and renal cell cancer [14]. Here, PDCD1 is linked to lung cancer.